Review




Structured Review

Janssen nipocalimab m281
Approved and clinical late-stage FcRn antagonists
Nipocalimab M281, supplied by Janssen, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/nipocalimab m281/product/Janssen
Average 90 stars, based on 1 article reviews
nipocalimab m281 - by Bioz Stars, 2026-02
90/100 stars

Images

1) Product Images from "Structure and function of therapeutic antibodies approved by the US FDA in 2023"

Article Title: Structure and function of therapeutic antibodies approved by the US FDA in 2023

Journal: Antibody Therapeutics

doi: 10.1093/abt/tbae007

Approved and clinical late-stage FcRn antagonists
Figure Legend Snippet: Approved and clinical late-stage FcRn antagonists

Techniques Used:



Similar Products

93
MedChemExpress nipocalimab m281
Inhibition of endocytotic albumin and IgG uptake by the FcRn-blocking antibody <t>nipocalimab.</t> ASCs remained untreated or were preincubated for 2 h with different doses of nipocalimab (5, 15, 25 μg/mL), and the intracellular content of either Alexa-594 albumin ( n = 6) ( a ) or IgG ( n = 6) ( b ) was monitored after 1 h of incubation. Intracellular IgG was visualized by labeling with an anti IgG antibody conjugated with Alexa Fluor 488. Scale bars represent 10 μm. * , ** , *** p < 0.05, 0.01, 0.001 as compared to the untreated sample. c , d Inhibition of Ca 2+ oscillations by nipocalimab (25 μg/mL). c Untreated ASCs in serum-containing complete ASC cell culture medium. d Nipocalimab-treated sample. Shown are representative traces derived from n = 12 experiments.
Nipocalimab M281, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/nipocalimab m281/product/MedChemExpress
Average 93 stars, based on 1 article reviews
nipocalimab m281 - by Bioz Stars, 2026-02
93/100 stars
  Buy from Supplier

90
Momenta Pharma nipocalimab m281 antibody
Inhibition of endocytotic albumin and IgG uptake by the FcRn-blocking antibody <t>nipocalimab.</t> ASCs remained untreated or were preincubated for 2 h with different doses of nipocalimab (5, 15, 25 μg/mL), and the intracellular content of either Alexa-594 albumin ( n = 6) ( a ) or IgG ( n = 6) ( b ) was monitored after 1 h of incubation. Intracellular IgG was visualized by labeling with an anti IgG antibody conjugated with Alexa Fluor 488. Scale bars represent 10 μm. * , ** , *** p < 0.05, 0.01, 0.001 as compared to the untreated sample. c , d Inhibition of Ca 2+ oscillations by nipocalimab (25 μg/mL). c Untreated ASCs in serum-containing complete ASC cell culture medium. d Nipocalimab-treated sample. Shown are representative traces derived from n = 12 experiments.
Nipocalimab M281 Antibody, supplied by Momenta Pharma, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/nipocalimab m281 antibody/product/Momenta Pharma
Average 90 stars, based on 1 article reviews
nipocalimab m281 antibody - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier

90
Janssen nipocalimab m281
Approved and clinical late-stage FcRn antagonists
Nipocalimab M281, supplied by Janssen, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/nipocalimab m281/product/Janssen
Average 90 stars, based on 1 article reviews
nipocalimab m281 - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier

93
MedChemExpress mcx3cr1 m281 mice
Approved and clinical late-stage FcRn antagonists
Mcx3cr1 M281 Mice, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/mcx3cr1 m281 mice/product/MedChemExpress
Average 93 stars, based on 1 article reviews
mcx3cr1 m281 mice - by Bioz Stars, 2026-02
93/100 stars
  Buy from Supplier

90
Janssen nipocalimab/m281
Approved and clinical late-stage FcRn antagonists
Nipocalimab/M281, supplied by Janssen, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/nipocalimab/m281/product/Janssen
Average 90 stars, based on 1 article reviews
nipocalimab/m281 - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier

90
Momenta Pharma nipocalimab (m281)
Investigational monoclonal antibodies in late-stage clinical studies for non-cancer indications*
Nipocalimab (M281), supplied by Momenta Pharma, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/nipocalimab (m281)/product/Momenta Pharma
Average 90 stars, based on 1 article reviews
nipocalimab (m281) - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier

90
Momenta Pharma nipocalimab m281
Investigational monoclonal antibodies in late-stage clinical studies for non-cancer indications*
Nipocalimab M281, supplied by Momenta Pharma, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/nipocalimab m281/product/Momenta Pharma
Average 90 stars, based on 1 article reviews
nipocalimab m281 - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier

Image Search Results


Inhibition of endocytotic albumin and IgG uptake by the FcRn-blocking antibody nipocalimab. ASCs remained untreated or were preincubated for 2 h with different doses of nipocalimab (5, 15, 25 μg/mL), and the intracellular content of either Alexa-594 albumin ( n = 6) ( a ) or IgG ( n = 6) ( b ) was monitored after 1 h of incubation. Intracellular IgG was visualized by labeling with an anti IgG antibody conjugated with Alexa Fluor 488. Scale bars represent 10 μm. * , ** , *** p < 0.05, 0.01, 0.001 as compared to the untreated sample. c , d Inhibition of Ca 2+ oscillations by nipocalimab (25 μg/mL). c Untreated ASCs in serum-containing complete ASC cell culture medium. d Nipocalimab-treated sample. Shown are representative traces derived from n = 12 experiments.

Journal: Cells, Tissues, Organs

Article Title: Endocytotic Albumin Uptake Pathways in Human Adipose Stem Cells and Connection to Intracellular Calcium Oscillations and the Neonatal Fc receptor

doi: 10.1159/000545773

Figure Lengend Snippet: Inhibition of endocytotic albumin and IgG uptake by the FcRn-blocking antibody nipocalimab. ASCs remained untreated or were preincubated for 2 h with different doses of nipocalimab (5, 15, 25 μg/mL), and the intracellular content of either Alexa-594 albumin ( n = 6) ( a ) or IgG ( n = 6) ( b ) was monitored after 1 h of incubation. Intracellular IgG was visualized by labeling with an anti IgG antibody conjugated with Alexa Fluor 488. Scale bars represent 10 μm. * , ** , *** p < 0.05, 0.01, 0.001 as compared to the untreated sample. c , d Inhibition of Ca 2+ oscillations by nipocalimab (25 μg/mL). c Untreated ASCs in serum-containing complete ASC cell culture medium. d Nipocalimab-treated sample. Shown are representative traces derived from n = 12 experiments.

Article Snippet: Subconfluent live ASCs were incubated with nipocalimab (M281) (MedChemExpress, cat. No. HY-P99037) at concentrations of 5, 15 and 25 μg/mL.

Techniques: Inhibition, Blocking Assay, Incubation, Labeling, Cell Culture, Derivative Assay

Approved and clinical late-stage FcRn antagonists

Journal: Antibody Therapeutics

Article Title: Structure and function of therapeutic antibodies approved by the US FDA in 2023

doi: 10.1093/abt/tbae007

Figure Lengend Snippet: Approved and clinical late-stage FcRn antagonists

Article Snippet: Nipocalimab (M281) , Janssen R&D (Momenta) , Phase 3 (NCT05912517) , MG, HDFN, RA, SLE, wAIHA , Human IgG1λ R120K, N296A, ΔK445 , IV infusion Q2W , [ , ] .

Techniques:

Investigational monoclonal antibodies in late-stage clinical studies for non-cancer indications*

Journal: mAbs

Article Title: Antibodies to watch in 2021

doi: 10.1080/19420862.2020.1860476

Figure Lengend Snippet: Investigational monoclonal antibodies in late-stage clinical studies for non-cancer indications*

Article Snippet: Momenta Pharmaceuticals , Nipocalimab (M281) , Human IgG1 , FcRn , Phase 2/3 , Warm autoimmune hemolytic anemia (NCT04119050).

Techniques: Bioprocessing, Virus, Infection